Literature DB >> 21886169

Action of novel CD37 antibodies on chronic lymphocytic leukemia cells.

G Krause, M Patz, P Isaeva, M Wigger, I Baki, V Vondey, S Kerwien, M Kuckertz, R Brinker, J Claasen, L P Frenzel, C-M Wendtner, K-H Heider, M Hallek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21886169     DOI： 10.1038/leu.2011.233

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

Review 1.  CD19 as an attractive target for antibody-based therapy.

Authors:  Ohad Hammer
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

Review 2.  Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.

Authors:  M A Kharfan-Dabaja; W G Wierda; L J N Cooper
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

3.  Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL.

Authors:  De-Kuan Chang; Vinodh B Kurella; Subhabrata Biswas; Yuval Avnir; Jianhua Sui; Xueqian Wang; Jiusong Sun; Yanyan Wang; Madhura Panditrao; Eric Peterson; Aimee Tallarico; Stacey Fernandes; Margaret Goodall; Quan Zhu; Jennifer R Brown; Roy Jefferis; Wayne A Marasco
Journal:  MAbs       Date:  2016-03-10       Impact factor: 5.857

4.  Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.

Authors:  Bo Yu; Yicheng Mao; Yuan Yuan; Chaofang Yue; Xinmei Wang; Xiaokui Mo; David Jarjoura; Michael E Paulaitis; Robert J Lee; John C Byrd; L James Lee; Natarajan Muthusamy
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

5.  Transcriptome profiles discriminate between Gram-positive and Gram-negative sepsis in preterm neonates.

Authors:  María Cernada; Alejandro Pinilla-González; Julia Kuligowski; José Manuel Morales; Sheila Lorente-Pozo; José David Piñeiro-Ramos; Anna Parra-Llorca; Inmaculada Lara-Cantón; Máximo Vento; Eva Serna
Journal:  Pediatr Res       Date:  2021-03-25       Impact factor: 3.756

6.  The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.

Authors:  K A Beckwith; F W Frissora; M R Stefanovski; W H Towns; C Cheney; X Mo; J Deckert; C M Croce; J M Flynn; L A Andritsos; J A Jones; K J Maddocks; G Lozanski; J C Byrd; N Muthusamy
Journal:  Leukemia       Date:  2014-01-21       Impact factor: 11.528

Review 7.  Tetraspanins as therapeutic targets in hematological malignancy: a concise review.

Authors:  Kyle A Beckwith; John C Byrd; Natarajan Muthusamy
Journal:  Front Physiol       Date:  2015-03-23       Impact factor: 4.566

8.  Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Authors:  S Betrian; L Ysebaert; K H Heider; J P Delord; J J Fournié; A Quillet-Mary
Journal:  Blood Cancer J       Date:  2016-11-11       Impact factor: 11.037

9.  Expression of MS4A and TMEM176 Genes in Human B Lymphocytes.

Authors:  Jonathan Zuccolo; Lili Deng; Tammy L Unruh; Ratna Sanyal; Jeremy A Bau; Jan Storek; Douglas J Demetrick; Joanne M Luider; Iwona A Auer-Grzesiak; Adnan Mansoor; Julie P Deans
Journal:  Front Immunol       Date:  2013-07-15       Impact factor: 7.561

10.  Effect of an anti-human Co-029/tspan8 mouse monoclonal antibody on tumor growth in a nude mouse model.

Authors:  Naouel Ailane; Céline Greco; Yingying Zhu; Monica Sala-Valdés; Martine Billard; Ibrahim Casal; Olivia Bawa; Paule Opolon; Eric Rubinstein; Claude Boucheix
Journal:  Front Physiol       Date:  2014-09-19       Impact factor: 4.566
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.